Clinical trials: Elevated Intraocular Pressure
Glaucoma, Open-Angle, Ocular Hypertension
Study of Rhopressa® for the Reduction of Elevated Intraocular Pressure in Patients With Glaucoma or Ocular Hypertension in a Real-world Setting
To evaluate the IOP lowering efficacy of netarsudil ophthalmic solution 0.02% when used as monotherapy or when used concomitantly with other IOP-lowering agents in subjects with elevated IOP due to open angle glaucoma or ocular…
- Trial name
- NCT03808688
- Testing
- Netarsudil Ophthalmic Solution 0.02%
- Where
- 22 sites in United States
- Volunteers
- 261 people
- Sponsor
- Aerie Pharmaceuticals
Ocular Hypertension, Glaucoma
Safety and Efficacy of Bimatoprost Compared With Latanoprost in Patients With Glaucoma or Ocular Hypertension
The study will compare the safety and efficacy of Bimatoprost and Latanoprost in patients with glaucoma or ocular hypertension
- Trial name
- NCT00541242
- Testing
- bimatoprost 0.03% eye drops, latanoprost 0.005% eye drops
- Where
- United States
- Volunteers
- 586 people
- Sponsor
- Allergan
Glaucoma, Ocular Hypertension
Efficacy and Safety Assessment of T4090 Ophthalmic Solution Versus Rhopressa® Ophthalmic Solution in Patients With Open-angle Glaucoma or Ocular Hypertension
The main purpose is to compare the ocular hypotensive efficacy and safety of two concentrations of T4090 (Kinezodianone R HCl 0.2% and 0.3%) ophthalmic solution with Rhopressa® ophthalmic solution
- Trial name
- NCT06394973
- Testing
- T4090 0.2%, T4090 0.3%, Rhopressa®
- Where
- 24 sites in United States
- Volunteers
- 161 people
- Sponsor
- Laboratoires Thea
Retinal Degeneration, Primary Open-angle Glaucoma
Intravitreal Mesenchymal Stem Cell Transplantation in Advanced Glaucoma.
Bone marrow-derived mesenchymal stem cells (MSC) therapy is a promising treatment for several degenerative diseases, including retinopathies and glaucoma, however no previous safety study involving humans has been conducted.
- Trial name
- NCT02330978
- Testing
- Intravitreal transplantation of mesenchymal stem cell, Culture and isolation of autologous bone-marrow mesenchymal stem cells
- Where
- Brazil
- Volunteers
- 2 people
- Sponsor
- University of Sao Paulo
Open Angle Glaucoma
Ologen Collagen Matrix Safety and Effective Comparison With Mitomycin-C(MMC) in Glaucoma Surgery
To compare the safety and effectiveness of oculusgen (ologen) collagen matrix implantation and Mitomycin-C(MMC) in glaucoma surgery.
- Trial name
- NCT00538590
- Testing
- Collagen Matrix in Glaucoma Filtering Surgery, Mitomycin-C(MMC) and glaucoma filtering surgery
- Where
- Germany
- Volunteers
- 20 people
- Sponsor
- Pro Top & Mediking Company Limited
Glaucoma
SENSIMED Triggerfish Safety and Tolerability
The purpose of this investigation is to study the safety and tolerability of SENSIMED Triggerfish, a soft contact lens-based device intended to continuously record relative changes in intraocular pressure (IOP).
- Trial name
- NCT01319617
- Testing
- SENSIMED Triggerfish
- Where
- United States
- Volunteers
- 41 people
- Sponsor
- Sensimed AG
Exfoliation Syndrome, Ocular Hypertension
A Prospective Study to Assess the Hypotensive Efficacy of Rho-Kinase Inhibitor AR-12286 Ophthalmic Solution 0.5% and 0.7% in Patients With Exfoliation Syndrome and Ocular Hypertension or Glaucoma
Glaucoma is the world's the second leading cause of irreversible blindness. The World Health Organization (WHO) estimated the incidence of blindness due to glaucoma to be 4.4 million people worldwide in 2002.
- Conditions
- Exfoliation Syndrome, Ocular Hypertension, Open Angle Glaucoma
- Trial name
- ROCK (NCT01936389)
- Testing
- AR-12286
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Robert Ritch, MD, LLC.
Glaucoma, Ocular Hypertension
Safety and Efficacy of Different Formulations of Bimatoprost Ophthalmic Solution in Patients With Glaucoma or Ocular Hypertension
This study will evaluate the safety and efficacy of bimatoprost 0.03% formulation B ophthalmic solution with LUMIGAN® (bimatoprost ophthalmic solution 0.03%) once daily for 12 weeks in patients with glaucoma or ocular hypertension
- Trial name
- NCT01099774
- Testing
- Bimatoprost 0.03% Formulation B Ophthalmic Solution, Bimatoprost 0.03% Ophthalmic Solution
- Where
- United States
- Volunteers
- 597 people
- Sponsor
- Allergan
Primary Open Angle Glaucoma, Ocular Hypertension
Non-inferiority of PRO-067 Ophthalmic Solution vs GAAP Ofteno® in Glaucoma or Ocular Hypertension
Aim: To demonstrate the non-inferiority of the PRO-067 ophthalmic solution manufactured by Laboratorios Sophia S.A. de C.V. versus GAAP Ofteno® ophthalmic solution like hypotensive therapy in subjects with primary open angle…
- Trial name
- COMPLIANCE (NCT02801617)
- Testing
- PRO-067, GAAP Ofteno®
- Where
- Mexico
- Volunteers
- 116 people
- Sponsor
- Laboratorios Sophia S.A de C.V.
Glaucoma, Open-Angle, Ocular Hypertension
A Study of Patients With Primary Open Angle Glaucoma or Ocular Hypertension Who Were Insufficiently Responsive to Monotherapy
This is a retrospective chart review and will assess changes in IOP after treatment with any fixed combination in patients who previously received monotherapy.
- Trial name
- NCT01637246
- Testing
- Any Fixed Combination Therapy
- Where
- Spain
- Volunteers
- 4,385 people
- Sponsor
- Allergan
Open-Angle Glaucoma, Ocular Hypertension
Evaluation of Intraocular Pressure Using Simbrinza™ in Patients With Open-Angle Glaucoma or Ocular Hypertension
The purpose of this study is to evaluate intraocular pressure (IOP) over a 24-hour period using Simbrinza™ topical ophthalmic suspension.
- Trial name
- NCT01978600
- Testing
- Brinzolamide 1%/Brimonidine 0.2% ophthalmic suspension, Timolol Maleate 0.5%
- Volunteers
- 89 people
- Sponsor
- Alcon Research
Glaucoma
12-Month Stability of Diurnal IOP Control on Cosopt
To determine the stability of diurnal intraocular pressure in eyes with glaucoma treated with Cosopt
- Trial name
- NCT00379834
- Testing
- Cosopt
- Volunteers
- 10 people
- Sponsor
- West Virginia University
Glaucoma and Ocular Hypertension
A Phase III Study Assessing the Efficacy and Safety of DE-117 Ophthalmic Solution Compared With Timolol Maleate Ophthalmic Solution 0.5% in Subjects With Glaucoma or Ocular Hypertension - Spectrum 4 Study
This is a Phase III, randomized, double-masked, active-controlled, parallel-group, multi-center study. Subjects diagnosed with glaucoma or OHT who meet eligibility criteria at Visit 1 (Screening) will washout of their current…
- Trial name
- NCT03691662
- Testing
- DE-117 Ophthalmic Solution, Timolol Maleate Ophthalmic Solution 0.5%
- Where
- 34 sites in United States
- Volunteers
- 417 people
- Sponsor
- Santen Inc.
Glaucoma
Does Using a Low Vision Aid Device Improve Quality of Life in Glaucoma Patients?
To determine the impact of OrCam over 1 month on health-related quality of life (HRQoL) in subjects with advanced glaucoma using the National Eye Institute Visual Function Questionnaire 25 (NEI-VFQ-25).
- Trial name
- NCT02526680
- Testing
- OrCam
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- Wills Eye
Glaucoma
Lucentis Versus Mitomycin C During Glaucoma Surgery
Does a new add on (or adjunctive) therapy used in glaucoma surgery improve the success of trabeculectomy? Ranibizumab may offer benefit similar to mitomycin C in preventing epi-scleral fibrosis while avoiding the well known…
- Trial name
- NCT00626782
- Testing
- Ranibizumab, Mitomycin (MMC)
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Wills Eye
Elevated Intraocular Pressure (IOP)
Safety and Intraocular Lowering Effect of Delivery of Travoprost Evolute® in Subjects With Elevated Intraocular Pressure
This is a pilot, open-label, multi-center clinical study. Each potential subject that has met all screening inclusion/exclusion criteria will undergo a six-week washout phase where they will discontinue the use of their topical…
- Trial name
- NCT04962009
- Testing
- Travoprost Evolute® (Travoprost Punctal Plug Delivery System), 166 ug
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Mati Therapeutics Inc.
Open-Angle Glaucoma, Ocular Hypertension
Nebivolol 0.5, 1.0, or Timolol 0.5 Suspension Compared to Timolol 0.5 Solution to Treat Glaucoma/Ocular Hypertension
The purpose of this study is to evaluate the safety (in the eye and throughout the body) and effectiveness of nebivolol (0.5 and 1 percent) and timolol (0.5 percent) eye drop suspensions.
- Trial name
- NCT04910100
- Testing
- Nebivolol Ophthalmic Suspension 1 Percent, Nebivolol Ophthalmic Suspension 0.5 Percent, Timolol Ophthalmic Suspension 0.5 Percent
- Where
- United States
- Volunteers
- 226 people
- Sponsor
- Betaliq, Inc.
Ocular Hypertension, Glaucoma
Study of Netarsudil (AR-13324) Ophthalmic Solution in Patients With Glaucoma or Ocular Hypertension
The purpose of this study is to evaluate the ocular and systemic safety of Netarsudil (AR-13324) Ophthalmic Solution, 0.02% q.d. and b.i.d. for 12 months compared to the active comparator Timolol Maleate Ophthalmic Solution, 0.5%.
- Trial name
- NCT02246764
- Testing
- AR-13324 Ophthalmic Solution 0.02%, AR-13324 Ophthalmic Solution 0.02% BID, Timolol maleate Ophthalmic Solution 0.5% BID
- Where
- United States
- Volunteers
- 93 people
- Sponsor
- Aerie Pharmaceuticals
Open Angle Glaucoma
Subconjunctival Versus Direct Mitomycin C in Trabeculectomy
Trabeculectomy is routinely used as a surgical treatment for open angle glaucoma. Success of trabeculectomy is greatly augmented by the use of antimetabolites to inhibit wound healing, specifically Mitomycin C (MMC).
- Trial name
- NCT04352660
- Testing
- Mitomycin-C injection, Mitomycin-C sponge
- Volunteers
- 100 people
- Sponsor
- University of California, San Diego
Glaucoma, Ocular Hypertension
A Phase IV Study of Travoprost + Brinzolamide to Treat Glaucoma or Ocular Hypertension
Double blind, crossover randomized, multicentric study to compare efficacy and tolerability of concomitant administration of travoprost and brinzolamide versus timolol-dorzolamide fixed combination in patients with glaucoma or…
- Trial name
- NCT00471380
- Testing
- travoprost 0.004% and brinzolamide 1%, fixed combination of timolol 0.5% and dorzolamide 2% plus travoprost vehicle
- Where
- Italy
- Volunteers
- 46 people
- Sponsor
- Alcon Research